Humacyte reported a Q loss of $0.13 per share, in line with the Zacks consensus and improved from a $0.16 loss a year ago (loss narrowed by $0.03, ~19% y/y). The result is essentially a meet with a modest year-over-year improvement but no change to guidance or other forward-looking detail provided.
Humacyte reported a Q loss of $0.13 per share, in line with the Zacks consensus and improved from a $0.16 loss a year ago (loss narrowed by $0.03, ~19% y/y). The result is essentially a meet with a modest year-over-year improvement but no change to guidance or other forward-looking detail provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
